Hypermarcas (OTCMKTS:HYPMY - Get Free Report) shares saw unusually-strong trading volume on Monday . Approximately 37,014 shares changed hands during trading, an increase of 112% from the previous session's volume of 17,424 shares.The stock last traded at $4.83 and had previously closed at $4.85.
Hypermarcas Stock Performance
The stock has a fifty day moving average of $4.33 and a 200-day moving average of $3.61. The firm has a market capitalization of $3.06 billion, a P/E ratio of 20.12 and a beta of 0.79. The company has a quick ratio of 0.80, a current ratio of 1.26 and a debt-to-equity ratio of 0.63.
Hypermarcas (OTCMKTS:HYPMY - Get Free Report) last announced its quarterly earnings data on Wednesday, April 23rd. The company reported ($0.04) EPS for the quarter. The business had revenue of $184.34 million during the quarter. Hypermarcas had a return on equity of 6.95% and a net margin of 12.51%.
Hypermarcas Announces Dividend
The business also recently announced a dividend, which will be paid on Friday, January 8th. Investors of record on Tuesday, July 1st will be given a $0.0345 dividend. This represents a dividend yield of 2.81%. The ex-dividend date of this dividend is Monday, June 30th. Hypermarcas's dividend payout ratio is currently 45.83%.
Hypermarcas Company Profile
(
Get Free Report)
Hypera SA operates as a pharmaceutical company in Brazil. It offers prescription products under the Adacne, Addera, apri, AmpliumG, please, Celestamine, Celestone, Celestone Soluspan, Cizax, deciprax, Derive C Micro, Micro Drift, Dermotil Fusid, Digedrat, diprogent, Diprosalic, Diprosone, diprospan, Emprol XR, Flow, Garasone, Halobex, Lipanon, moon, Lydian, macrodantin, Max Sulid, milgamma, Mioflex A, nesina, Novotram, oximax, peridal, Peridal Suspension, PredSim, Pressaliv, Quadriderm, Rizi, Rizi M, softalm, tacroz, tinodin, umma, and velunid brands.
Recommended Stories
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider Hypermarcas, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Hypermarcas wasn't on the list.
While Hypermarcas currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Market downturns give many investors pause, and for good reason. Wondering how to offset this risk? Enter your email address to learn more about using beta to protect your portfolio.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
